This article is more than 5 years old. Information may no longer be current.

Mazzo named executive chairman of Neurotech

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Neurotech Pharmaceuticals has tapped James Mazzo, former CEO of Abbott Medical Optics, as executive chairman to help advance the biotechnology company’s therapies for chronic retinal disease toward market availability, according to a company news release.

Last month, Mazzo was also named as operating partner for Versant Ventures, as well as chairman and CEO of AcuFocus, a company within the Versant portfolio.

Neurotech’s core technology platform is a patented genetically engineered implant designed to allow for continuous delivery of protein drugs directly into the vitreous, the release said. The Encapsulated Cell Technology platform could eliminate the need for monthly injections by treating a diseased retina for 2 years or more.

It may be possible to adapt the Encapsulated Cell Technology platform to generate protein drugs that can target uveitis, glaucoma and other ophthalmic indications, according to the release.